Exemestane (Aromasin) CAS.107868-30-4 | Forum

Topic location: Forum home » General » General Chat
xysoom
xysoom Sep 7 '19
Exemestane (Aromasin) CAS.107868-30-4



Buy Exemestane powder, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be calledestrogen-responsive,hormonally-responsive,or hormone-receptor-positive.Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.

2.Specifications:

Other name: Aromasin
Product Category: Pharmaceutical raw materials and intermediates
Product content: ≥ 99%
CAS Number: 107868-30-4
Molecular formula: C20H24O2
Molecular Weight:296.40
Packing specifications: 25kg / barrel
Molecular weight: 296.4
Appearance: White or Almost White Crystalline Powder
Assay(by HPLC): 98.0-101.2%min

Effect: This product is an adrenal cortical hormone drugs. A variety of pharmacological effects of anti-inflammatory, anti allergic and immune suppression etc..

Usage:Developed to help fight breast cancer, Aromasin is one of the most powerful estrogen suppressing compounds available for body builders taking anabolic steroids. Additionally, it also raises testosterone in the body, which is a bonus for bodybuilders during post-cycle-therapy.

Delivery:EMS,DHL,FedEx ,TNT
Delivery time:within 8 hours after payment confirmed
Payment:T/T, Western Union,Money Gram and Bitcoin
3. Applications:

Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to it for completion of a total of five consecutive years of adjuvant hormonal therapy. US FDA approval was in October 2005.

Exemestane is also indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Share: